Across TCGA pan-cancer cohorts, ERCC6L mass-spec protein differs between tumor and matched normal tissue in 5 of 18 cancer types tested, making tumor–normal expression one of ERCC6L’s most consistent transcriptional readouts.
The strongest signal is observed in lung squamous cell carcinoma (LSCC), where ERCC6L mass-spec protein is more highly expressed in tumor relative to normal tissue. In most cancer types ERCC6L is over-expressed in tumor, although a few such as PDAC show the opposite, repressed pattern.
LSCC, LUAD, and HNSC are the cancer types where ERCC6L tumor–normal differential expression is most reproducible.
mass-spec protein tumor vs normal associations by lineage
Ranked by sampling consensus. Fold-change is the tumor-versus-normal difference in ERCC6L mass-spec protein (log2); positive values indicate higher expression in tumor. p-values are from the differential-expression test.